Back
Corporate News
Glenmark receives USFDA approval for expanded use of RYALTRIS' for pediatric patients
21-Jul-2026, 09:41
Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS' (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years.
Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS' (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years.
With this approval, RYALTRIS' is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population.